KR102434346B1 - B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 - Google Patents

B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 Download PDF

Info

Publication number
KR102434346B1
KR102434346B1 KR1020207029321A KR20207029321A KR102434346B1 KR 102434346 B1 KR102434346 B1 KR 102434346B1 KR 1020207029321 A KR1020207029321 A KR 1020207029321A KR 20207029321 A KR20207029321 A KR 20207029321A KR 102434346 B1 KR102434346 B1 KR 102434346B1
Authority
KR
South Korea
Prior art keywords
base
artificial sequence
modified
mod
dsrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207029321A
Other languages
English (en)
Korean (ko)
Other versions
KR20200122397A (ko
Inventor
다니엘 친
요헨 데커트
마르쿠스 호스바흐
마티아스 존
Original Assignee
애로우헤드 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애로우헤드 파마슈티컬스 인코포레이티드 filed Critical 애로우헤드 파마슈티컬스 인코포레이티드
Priority to KR1020217028122A priority Critical patent/KR102434357B1/ko
Publication of KR20200122397A publication Critical patent/KR20200122397A/ko
Application granted granted Critical
Publication of KR102434346B1 publication Critical patent/KR102434346B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207029321A 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 Active KR102434346B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217028122A KR102434357B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP11172235 2011-06-30
EP11172235.1 2011-06-30
US13/535,454 2012-06-28
KR1020197027444A KR102167524B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
PCT/US2012/044505 WO2013003520A1 (en) 2011-06-30 2012-06-28 Compositions and methods for inhibiting gene expression of hepatitis b virus
US13/535,454 US8809293B2 (en) 2011-06-30 2012-06-28 Compositions and methods for inhibiting gene expression of hepatitis B virus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197027444A Division KR102167524B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028122A Division KR102434357B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20200122397A KR20200122397A (ko) 2020-10-27
KR102434346B1 true KR102434346B1 (ko) 2022-08-18

Family

ID=47391267

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020207029321A Active KR102434346B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
KR1020197027444A Active KR102167524B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
KR1020227028219A Active KR102554783B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
KR1020137031029A Active KR102025295B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
KR1020217028122A Active KR102434357B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020197027444A Active KR102167524B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
KR1020227028219A Active KR102554783B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
KR1020137031029A Active KR102025295B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
KR1020217028122A Active KR102434357B1 (ko) 2011-06-30 2012-06-28 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법

Country Status (21)

Country Link
US (2) US8809293B2 (enExample)
EP (3) EP3901263A1 (enExample)
JP (5) JP6165723B2 (enExample)
KR (5) KR102434346B1 (enExample)
CN (3) CN113430196B (enExample)
AU (5) AU2012275355B2 (enExample)
BR (1) BR112013031021A2 (enExample)
CA (2) CA3064103C (enExample)
DK (1) DK2726613T3 (enExample)
EA (4) EA202090994A1 (enExample)
ES (1) ES2690538T3 (enExample)
HR (1) HRP20181564T1 (enExample)
IL (3) IL230226B (enExample)
MX (2) MX342731B (enExample)
PL (1) PL2726613T3 (enExample)
PT (1) PT2726613T (enExample)
SG (1) SG194751A1 (enExample)
SI (1) SI2726613T1 (enExample)
TW (5) TW202244278A (enExample)
WO (1) WO2013003520A1 (enExample)
ZA (1) ZA201307914B (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
EP3505528B1 (en) 2011-04-21 2020-11-25 Ionis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
KR102434346B1 (ko) * 2011-06-30 2022-08-18 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
CA2883785C (en) 2012-08-30 2020-08-18 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections
US20150291958A1 (en) 2012-11-15 2015-10-15 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
US20150368642A1 (en) 2013-01-30 2015-12-24 Hoffmann-La Roche Inc. Lna oligonucleotide carbohydrate conjugates
EP3052627B1 (en) 2013-10-04 2018-08-22 Novartis AG Novel formats for organic compounds for use in rna interference
CN105792832B (zh) * 2013-10-04 2021-03-23 诺华股份有限公司 用于治疗乙肝病毒的有机化合物
WO2015051045A2 (en) 2013-10-04 2015-04-09 Novartis Ag 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
WO2016011123A1 (en) * 2014-07-16 2016-01-21 Arrowhead Research Corporation Organic compositions to treat apoc3-related diseases
CA2963271A1 (en) 2014-10-02 2016-04-07 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
JOP20200092A1 (ar) * 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
CA2970966A1 (en) * 2014-12-22 2016-06-30 Anapa Biotech A/S Dual quenching assay for multiplex detection of target nucleic acids
SG11201708679YA (en) * 2015-05-06 2017-11-29 Benitec Biopharma Ltd Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
WO2017015175A1 (en) * 2015-07-17 2017-01-26 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
HK1248278A1 (zh) * 2015-07-29 2018-10-12 Arbutus Biopharma Corporation 用於使乙型肝炎病毒基因表达沉默的组合物及方法
EP3332007A4 (en) * 2015-08-07 2019-07-17 Arrowhead Pharmaceuticals, Inc. RNAi Therapy Against Infection with Hepatitis B Virus
JO3769B1 (ar) * 2015-08-07 2021-01-31 Arrowhead Pharmaceuticals Inc علاج RNAi لعدوى فيروس التهاب الكبد B
KR102515329B1 (ko) * 2016-03-07 2023-03-29 애로우헤드 파마슈티컬스 인코포레이티드 치료용 화합물을 위한 표적화 리간드
EP3431591B1 (en) * 2016-03-09 2020-09-16 Tokyo University of Science Foundation Nucleic acid oligomer for rna hybrid formation
HUE053172T2 (hu) 2016-03-14 2021-06-28 Hoffmann La Roche Oligonukleotidok a PD-L1 expresszió csökkentésére
EP3452595A4 (en) * 2016-05-05 2020-02-19 Benitec Biopharma Limited REAGENTS FOR THE TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
KR102627418B1 (ko) * 2016-09-14 2024-01-19 얀센 바이오파마, 인크. 변형된 올리고뉴클레오티드 및 사용 방법
IL308894A (en) * 2016-10-14 2024-01-01 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
WO2018172852A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
SI3607069T1 (sl) 2017-04-05 2023-02-28 Silence Therapeutics Gmbh Produkti in sestavki
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
CA3059446A1 (en) * 2017-04-18 2018-10-25 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
CN118048356A (zh) 2017-10-16 2024-05-17 豪夫迈·罗氏有限公司 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
SG11202003488WA (en) * 2017-10-20 2020-05-28 Dicerna Pharmaceuticals Inc Methods for treating hepatitis b infection
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HRP20250277T1 (hr) 2017-12-01 2025-05-09 Suzhou Ribo Life Science Co., Ltd. Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
EP3718572B1 (en) 2017-12-01 2024-07-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
EP3719126B1 (en) 2017-12-01 2025-01-01 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
EP3732185B1 (en) 2017-12-29 2025-02-26 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
MA52661A (fr) 2018-04-05 2021-02-17 Centre Leon Berard Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
PE20210346A1 (es) 2018-07-03 2021-02-25 Hoffmann La Roche Oligonucleotidos para modular la expresion de tau
AU2019300324A1 (en) 2018-07-13 2021-01-21 F. Hoffmann-La Roche Ag Oligonucleotides for modulating RTEL1 expression
TWI869058B (zh) 2018-07-27 2025-01-01 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
EP3837366A1 (en) 2018-08-13 2021-06-23 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
CN111655849B (zh) 2018-08-21 2024-05-10 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. SHORT INTERFERENT RNA CONJUGATE, METHOD FOR PREPARATION AND USE THEREOF
CN109385459A (zh) * 2018-10-18 2019-02-26 大连理工大学 一种细胞分裂素通过抑制dna聚合酶活性抑制细胞增殖的方法
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CA3129261A1 (en) 2019-02-07 2020-08-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for hepatitis b virus infection
CN114072142A (zh) 2019-04-18 2022-02-18 杨森制药公司 用于治疗乙型肝炎病毒感染的组合疗法
TW202106294A (zh) 2019-04-18 2021-02-16 美商健生醫藥公司 用於治療ｂ型肝炎病毒感染的組合療法（一）
CN113227376B (zh) 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
AU2020297008A1 (en) * 2019-06-18 2022-02-17 Janssen Sciences Ireland Unlimited Company Combination of hepatitis B virus (HBV) vaccines and HBV-targeting RNAi
TW202114731A (zh) 2019-06-18 2021-04-16 愛爾蘭商健生科學愛爾蘭無限公司 B型肝炎病毒(HBV)疫苗與靶向HBV之RNAi之組合
CN110218728A (zh) 2019-06-28 2019-09-10 厦门甘宝利生物医药有限公司 一种新化合物及其应用
JP7653997B2 (ja) 2019-12-19 2025-03-31 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
WO2021122735A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sept9 inhibitors for treating hepatitis b virus infection
JP2023506540A (ja) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
WO2021122910A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sbds inhibitors for treating hepatitis b virus infection
JP2023506954A (ja) 2019-12-19 2023-02-20 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
TW202146011A (zh) 2020-03-05 2021-12-16 美商詹森藥物公司 治療b型肝炎病毒感染之組合療法
TW202208625A (zh) * 2020-03-06 2022-03-01 美商艾利格斯醫療公司 經修飾之短干擾核酸(siNA)分子及其用途
CN116157522A (zh) 2020-08-21 2023-05-23 豪夫迈·罗氏有限公司 A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
WO2022131883A1 (ko) * 2020-12-18 2022-06-23 올릭스 주식회사 HBV 발현을 억제하는 RNAi 제제 및 이의 용도
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
US20240299557A1 (en) * 2021-01-22 2024-09-12 Taibidi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound for degrading deoxyribonucleic acid (dna) polymerase, and use thereof
TW202246500A (zh) 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
WO2023109938A1 (zh) * 2021-12-16 2023-06-22 上海拓界生物医药科技有限公司 一种dsRNA、其制备方法及应用
JP2024546993A (ja) 2021-12-17 2024-12-26 エフ． ホフマン－ラ ロシュ アーゲー Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
CN119452087A (zh) * 2022-06-21 2025-02-14 正大天晴药业集团股份有限公司 用于抑制乙型肝炎病毒的双链核糖核酸
WO2024125636A1 (zh) * 2022-12-16 2024-06-20 上海拓界生物医药科技有限公司 Toll样受体调节剂与dsRNA的联合治疗
CN119331868A (zh) * 2023-07-18 2025-01-21 复旦大学 一种核酸、含有该核酸的药物组合物和缀合物及其应用
CN119913146A (zh) * 2023-09-28 2025-05-02 北京凯因科技股份有限公司 用于抑制乙型肝炎病毒的siRNA及其用途
CN119799705B (zh) * 2024-07-08 2025-12-12 杭州天龙药业有限公司 靶向调控HBV基因表达的siRNA及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124651A1 (en) 2001-12-04 2003-07-03 Vijaya Pasupuleti Oligonucleotides and methods for detecting hepatitis B viral nucleic acids
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US20080145346A1 (en) 2003-12-16 2008-06-19 Agency For Science, Technology And Research Methods And Compounds For Altering The Load Of Hepatitis Virus

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
ATE113059T1 (de) 1987-06-24 1994-11-15 Florey Howard Inst Nukleosid-derivate.
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
AU658562B2 (en) 1989-10-24 1995-04-27 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
CA2044593C (en) 1989-11-03 2004-04-20 Kenneth L. Brigham Method of in vivo delivery of functioning foreign genes
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5506351A (en) 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
AU2916292A (en) 1991-10-24 1993-05-21 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
JPH08508491A (ja) 1993-03-31 1996-09-10 スターリング ウインスロップ インコーポレイティド ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド
US5571902A (en) 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5856459A (en) * 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
CN1057302C (zh) * 1997-08-27 2000-10-11 中国科学院上海生物化学研究所 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸
US6271358B1 (en) 1998-07-27 2001-08-07 Isis Pharmaceuticals, Inc. RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
AU6430599A (en) 1998-10-09 2000-05-01 Cytogenix, Inc. Enzymatic synthesis of ssdna
US5977341A (en) 1998-11-20 1999-11-02 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-beta expression
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050032733A1 (en) * 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
WO2005019453A2 (en) * 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
EP1383782A1 (en) 2001-03-26 2004-01-28 Sirna Therpeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
PT1527176E (pt) 2002-08-05 2007-04-30 Atugen Ag Novas formas de muléculas de arn de interferência
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2004044139A2 (en) 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
EP1636385A4 (en) 2003-06-24 2010-06-02 Mirus Bio Corp INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS
US20080311126A1 (en) 2004-01-12 2008-12-18 Genesense Technologies, Inc Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer
WO2005116204A1 (ja) 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US20080255065A1 (en) 2004-08-18 2008-10-16 Genesense Technologies, Inc. Small Interfering Rna Molecules Against Ribonucleotide Reductase and Uses Thereof
US20080096839A1 (en) * 2005-03-09 2008-04-24 Mogam Biotechnology Research Institute Small Interfering Rna and Pharmaceutical Composition for Treatment of Hepatitis B Comprising the Same
KR20080036650A (ko) 2005-08-17 2008-04-28 시르나 쎄러퓨틱스 인코퍼레이티드 Ｒｎａ 간섭을 매개하는 화학적으로 변형된 짧은 간섭 핵산분자
CN101426912A (zh) * 2005-08-17 2009-05-06 瑟纳治疗公司 介导rna干扰的化学修饰短干扰核酸分子
RU2418068C2 (ru) * 2005-08-17 2011-05-10 Сирна Терапьютикс, Инк. Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
US20070197460A1 (en) 2005-11-01 2007-08-23 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
US8877917B2 (en) 2007-04-23 2014-11-04 Alnylam Pharmaceuticals, Inc. Glycoconjugates of RNA interference agents
WO2008146251A2 (en) * 2007-05-29 2008-12-04 University Of The Witwatersrand, Johannesburg A primary micro rna expression cassette
WO2009038266A1 (en) 2007-09-17 2009-03-26 Mogam Biotechnology Research Institute Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv
CA2930393C (en) 2007-12-04 2022-11-29 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
ES2536996T3 (es) 2009-07-06 2015-06-01 F. Hoffmann-La Roche Ag Anticuerpos biespecíficos de unión a digoxigenina
US20110152349A1 (en) * 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
EP2390327A1 (en) 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
WO2012037254A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. MODIFIED iRNA AGENTS
CN101948834B (zh) * 2010-09-16 2012-07-04 山东大学 用于治疗HBV的siRNA
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
EP3505528B1 (en) 2011-04-21 2020-11-25 Ionis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
KR102434346B1 (ko) * 2011-06-30 2022-08-18 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
RS59199B1 (sr) 2012-05-25 2019-10-31 Univ California Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
WO2015042447A1 (en) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
CN105792832B (zh) 2013-10-04 2021-03-23 诺华股份有限公司 用于治疗乙肝病毒的有机化合物
EP3811977B1 (en) 2014-05-01 2025-12-03 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
WO2017015175A1 (en) 2015-07-17 2017-01-26 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
HK1248278A1 (zh) 2015-07-29 2018-10-12 Arbutus Biopharma Corporation 用於使乙型肝炎病毒基因表达沉默的组合物及方法
EP3332007A4 (en) 2015-08-07 2019-07-17 Arrowhead Pharmaceuticals, Inc. RNAi Therapy Against Infection with Hepatitis B Virus
MA45478A (fr) 2016-04-11 2019-02-20 Arbutus Biopharma Corp Compositions de conjugués d'acides nucléiques ciblés
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US20030124651A1 (en) 2001-12-04 2003-07-03 Vijaya Pasupuleti Oligonucleotides and methods for detecting hepatitis B viral nucleic acids
US20080145346A1 (en) 2003-12-16 2008-06-19 Agency For Science, Technology And Research Methods And Compounds For Altering The Load Of Hepatitis Virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BMC Microbiology,제10권,214호,1-10면 (2010) 1부.*

Also Published As

Publication number Publication date
JP2014527401A (ja) 2014-10-16
NZ617756A (en) 2015-04-24
SI2726613T1 (sl) 2018-10-30
MX2020011807A (es) 2020-12-07
JP2017169568A (ja) 2017-09-28
EA201690497A3 (ru) 2016-12-30
IL270877A (en) 2020-01-30
EA201391394A1 (ru) 2014-05-30
EA201690497A2 (ru) 2016-08-31
AU2012275355A2 (en) 2014-02-13
US20130005793A1 (en) 2013-01-03
ZA201307914B (en) 2015-01-28
KR102167524B1 (ko) 2020-10-20
ES2690538T3 (es) 2018-11-21
CA2833778C (en) 2021-09-28
HRP20181564T1 (hr) 2018-11-30
IL270877B (en) 2021-10-31
CN103635576B (zh) 2016-09-21
JP2023179497A (ja) 2023-12-19
EP3418386A2 (en) 2018-12-26
EP2726613A1 (en) 2014-05-07
USRE48345E1 (en) 2020-12-08
MX342731B (es) 2016-10-11
KR20140028021A (ko) 2014-03-07
EP2726613A4 (en) 2014-12-10
CA3064103A1 (en) 2013-01-03
KR20220119522A (ko) 2022-08-29
JP6165723B2 (ja) 2017-07-19
AU2012275355B2 (en) 2017-05-11
TW201311716A (zh) 2013-03-16
TW202244278A (zh) 2022-11-16
IL230226B (en) 2019-12-31
MX2013013556A (es) 2014-02-27
AU2017210563B2 (en) 2019-10-10
JP6959293B2 (ja) 2021-11-02
AU2019240625A1 (en) 2019-10-17
EP3418386B1 (en) 2021-04-07
JP2019141077A (ja) 2019-08-29
WO2013003520A1 (en) 2013-01-03
KR20200122397A (ko) 2020-10-27
TWI786401B (zh) 2022-12-11
EA024762B9 (ru) 2017-04-28
CN106434665A (zh) 2017-02-22
EP2726613B1 (en) 2018-08-08
CN113430196B (zh) 2025-05-20
SG194751A1 (en) 2013-12-30
TWI695066B (zh) 2020-06-01
KR102554783B1 (ko) 2023-07-11
EA035756B1 (ru) 2020-08-05
HK1193633A1 (zh) 2014-09-26
US8809293B2 (en) 2014-08-19
KR102434357B1 (ko) 2022-08-18
AU2017210563A1 (en) 2017-08-24
TWI659040B (zh) 2019-05-11
AU2012275355A1 (en) 2013-10-31
EA202090994A1 (ru) 2020-08-31
AU2022206748A1 (en) 2022-08-18
EP3901263A1 (en) 2021-10-27
BR112013031021A2 (pt) 2018-10-09
DK2726613T3 (en) 2018-12-03
CA3064103C (en) 2023-03-07
KR20190111147A (ko) 2019-10-01
EP3418386A3 (en) 2019-04-24
TW202102673A (zh) 2021-01-16
CN106434665B (zh) 2021-06-08
EA024762B1 (ru) 2016-10-31
AU2022202365A1 (en) 2022-04-28
AU2019240625B2 (en) 2022-04-21
CN113430196A (zh) 2021-09-24
IL284578A (en) 2021-08-31
KR20210110900A (ko) 2021-09-09
EA202191537A1 (ru) 2022-01-31
PT2726613T (pt) 2018-10-26
TW201827594A (zh) 2018-08-01
CN103635576A (zh) 2014-03-12
PL2726613T3 (pl) 2019-02-28
TW202424196A (zh) 2024-06-16
CA2833778A1 (en) 2013-01-03
KR102025295B1 (ko) 2019-09-26
JP2021191274A (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
AU2019240625B2 (en) Compositions and methods for inhibiting gene expression of Hepatitis B virus
HK40064478A (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
NZ617756B2 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
EA045398B1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4